Mark W. Stahlhut

3.2k citations

45 papers · 1.7k indexed · h-index 21

Co-authors: David B. Olsen Hie‐Won Hann Steven S. Carroll H W Hann Lawrence C. Kuo B. S. Blumberg Carrie A. Rutkowski Malcolm MacCoss
Topics: HIV/AIDS drug development and treatment (31 papers)HIV Research and Treatment (18 papers)Hepatitis C virus research (17 papers)
Cited by: Hepatology Virology Infectious Diseases
Journals: Journal of the American Chemical Society Journal of Biological Chemistry Angewandte Chemie International Edition
Partner nations: United States Italy Canada

In The Last Decade

Mark W. Stahlhut

45 papers receiving 1.6k citations

Peers

Countries citing papers authored by Mark W. Stahlhut

Since Specialization

Citations

This map shows the geographic impact of Mark W. Stahlhut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Stahlhut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Stahlhut more than expected).

Fields of papers citing papers by Mark W. Stahlhut

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Stahlhut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Stahlhut. The network helps show where Mark W. Stahlhut may publish in the future.

Co-authorship network of co-authors of Mark W. Stahlhut

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Stahlhut. A scholar is included among the top collaborators of Mark W. Stahlhut based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Stahlhut. Mark W. Stahlhut is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A transient cell-based phenotype assay for hepatitis C NS3/4A protease: Application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV 2008 ·Journal of Virological Methods ·Steven W. Ludmerer,Donald J. Graham,Mihir Patel,Kevin F. Gilbert,Mark W. Stahlhut,David B. Olsen	13
2	Bismacrocyclic Inhibitors of Hepatitis C NS3/4a Protease 2008 ·Angewandte Chemie International Edition ·John A. McCauley,Michael T. Rudd,Kevin T. Nguyen,Charles McIntyre,Joseph J. Romano,Kimberly J. Bush,Sándor Varga,(unknown),Steven S. Carroll,Jillian DiMuzio,Mark W. Stahlhut,David B. Olsen,Terry A. Lyle,Joseph P. Vacca,Nigel J. Liverton	18
3	Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2′-C-methyladenosine 2007 ·Bioorganic & Medicinal Chemistry ·Gabor Butora,David B. Olsen,Steven S. Carroll,Daniel R. McMasters,Christoph Schmitt,Joseph F. Leone,Mark W. Stahlhut,Christine Burlein,Malcolm MacCoss	24
4	Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus 2007 ·Bioorganic & Medicinal Chemistry Letters ·Subharekha Raghavan,Zhijian Lu,(unknown),Kevin T. Chapman,William A. Schleif,David B. Olsen,Mark W. Stahlhut,Carrie A. Rutkowski,Lori J. Gabryelski,Emilio A. Emini,James R. Tata	8
5	Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2′ side chains 2005 ·Bioorganic & Medicinal Chemistry Letters ·Amos B. Smith,Adam K. Charnley,Hironori Harada,Jason J. Beiger,Louis‐David Cantin,(unknown),Ralph Hirschmann,Sanjeev Munshi,David B. Olsen,Mark W. Stahlhut,William A. Schleif,Lawrence C. Kuo	18
6	A genotype 2b NS5B polymerase with novel substitutions supports replication of a chimeric HCV 1b:2b replicon containing a genotype 1b NS3-5A background 2005 ·Antiviral Research ·Donald J. Graham,Mark W. Stahlhut,Osvaldo Flores,David B. Olsen,Daria J. Hazuda,Robert L. LaFemina,Steven W. Ludmerer	13
7	P1′ oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1 2004 ·Bioorganic & Medicinal Chemistry Letters ·Ronald M. Kim,(unknown),Kevin T. Chapman,William A. Schleif,David B. Olsen,Mark W. Stahlhut,Carrie A. Rutkowski,Emilio A. Emini,James R. Tata	21
8	Hinnuliquinone, a C2-symmetric dimeric non-peptide fungal metabolite inhibitor of HIV-1 protease 2004 ·Biochemical and Biophysical Research Communications ·Sheo B. Singh,John G. Ondeyka,(unknown),Carolyn L. Ruby,Vinod Sardana,Marvin Schulman,(unknown),Fernando Peláez,Mark W. Stahlhut,Sanjeev Munshi,David B. Olsen,Russell B. Lingham	33
9	HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1′ substituent 2003 ·Bioorganic & Medicinal Chemistry Letters ·Joseph Duffy,Brian A. Kirk,(unknown),Kevin T. Chapman,William A. Schleif,David B. Olsen,Mark W. Stahlhut,Carrie A. Rutkowski,Lawrence C. Kuo,Lixia Jin,Jiunn H. Lin,Emilio A. Emini,James R. Tata	10
10	Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs 2003 ·Journal of Biological Chemistry ·Steven S. Carroll,Joanne E. Tomassini,Michele Bosserman,Krista Getty,Mark W. Stahlhut,Anne B. Eldrup,Balkrishen Bhat,Dawn L. Hall,(unknown),Robert L. LaFemina,Carrie A. Rutkowski,B. Wolanski,Zhucheng Yang,Giovanni Migliaccio,Raffaele De Francesco,Lawrence C. Kuo,Malcolm MacCoss,David B. Olsen	281
11	Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus 2003 ·Bioorganic & Medicinal Chemistry Letters ·Zhijian Lu,Subharekha Raghavan,(unknown),Mark G. Charest,Mark W. Stahlhut,Carrie A. Rutkowski,(unknown),David B. Olsen,William A. Schleif,Anthony Carella,Lori J. Gabryelski,Lixia Jin,Jiunn H. Lin,Emilio A. Emini,Kevin T. Chapman,James R. Tata	12
12	Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2′ 2002 ·Bioorganic & Medicinal Chemistry Letters ·Subharekha Raghavan,Zheng Rong Yang,Ralph T. Mosley,William A. Schleif,Lori J. Gabryelski,David B. Olsen,Mark W. Stahlhut,Lawrence C. Kuo,Emilio A. Emini,Kevin T. Chapman,James R. Tata	6
13	Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-Resistant viral strains 2002 ·Bioorganic & Medicinal Chemistry Letters ·Yuan Cheng,Fengqi Zhang,Thomas A. Rano,Zhijian Lu,William A. Schleif,Lori J. Gabryelski,David B. Olsen,Mark W. Stahlhut,Carrie A. Rutkowski,Jiunn H. Lin,Lixia Jin,Emilio A. Emini,Kevin T. Chapman,James R. Tata	23
14	A Combinatorial Library of Indinavir Analogues and Its In Vitro and In Vivo Studies 2002 ·Bioorganic & Medicinal Chemistry Letters ·Yuan Cheng,Thomas A. Rano,(unknown),Fengqi Zhang,Zhijian Lu,William A. Schleif,Lori J. Gabryelski,David B. Olsen,Mark W. Stahlhut,Lawrence C. Kuo,Jiunn H. Lin,Xin Xu,Lixia Jin,Timothy Olah,Debra A. McLoughlin,(unknown),Kevin T. Chapman,James R. Tata	6
15	Elucidation of Basic Mechanistic and Kinetic Properties of Influenza Endonuclease Using Chemically Synthesized RNAs 1996 ·Journal of Biological Chemistry ·David B. Olsen,Fritz Benseler,James L. Cole,Mark W. Stahlhut,Robert E. Dempski,Paul L. Darke,Lawrence C. Kuo	20
16	[8] Expression and purification of retroviral HIV-1 reverse transcriptase 1996 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Mark W. Stahlhut,David B. Olsen	10
17	Sensitivity of HIV-1 Reverse Transcriptase and Its Mutants to Inhibition by Azidothymidine Triphosphate 1994 ·Biochemistry ·Steven S. Carroll,James Geib,David B. Olsen,Mark W. Stahlhut,Jules A. Shafer,Lawrence C. Kuo	51
18	Purification and Characterization of HIV-1 Reverse Transcriptase Having a 1:1 Ratio of p66 and p51 Subunits 1994 ·Protein Expression and Purification ·Mark W. Stahlhut,(unknown),Jon H. Condra,Jing-Li Fu,L Gotlib,Donald J. Graham,David B. Olsen	9
19	Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice 1992 ·Cancer ·Hie‐Won Hann,Mark W. Stahlhut,Raphael Rubin,Willis C. Maddrey	85
20	Iron enhances tumor growth. Observation on spontaneous mammary tumors in mice 1991 ·Cancer ·Hie‐Won Hann,Mark W. Stahlhut,Hyman Menduke	61

About Mark W. Stahlhut

Mark W. Stahlhut is a scholar working on Virology, Hepatology and Infectious Diseases, having authored 45 papers that have together received 1.7k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (31 papers), HIV Research and Treatment (18 papers) and Hepatitis C virus research (17 papers). The work is most often cited by research in Hepatology (472 citations), Virology (252 citations) and Infectious Diseases (656 citations). Mark W. Stahlhut has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include David B. Olsen, Hie‐Won Hann, Steven S. Carroll, H W Hann, Lawrence C. Kuo, B. S. Blumberg, Carrie A. Rutkowski, Malcolm MacCoss, Christine L. Hann and Joanne E. Tomassini. Their work appears in journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Angewandte Chemie International Edition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact